44
[1] Berne R.M., Levy M.N. Fisiologia, 4a Ed., 28.
[2] Quayle JM, Standen NB; KATP channels in vascular smooth muscle. Cardiovasc. Res. 1994, 28 (6), 797-804.
[3] Amoroso S., Schmid-Antomarchi H., Fosset M., Lazdunski M.; Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive K+ channels. Science
1990, 247, 852-854.
[4]Noma A.; ATP-regulated K + channels in cardiac muscle; Nature, 1983, 305, 147. [5] El-Hashim AZ, Buchheit KH, Fozard J, Page C; Effect of the K+ (ATP) channel opener, KCO912, on baseline and allergen induced airway hyperresponsiveness in allergic rabbits. Eur. J. Pharmacol. 2004; 484(2-3):351-6.
[6] Pelaia G., Gallelli L., Vatrella A., et al.; Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. Life Sci.
2002;70(9):977-90.
[7] Gopalakrishnan M., Shieh CC.; Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Exp Opin Ther Targets 2004;8:437-58.
[8] De Tullio P., Lebrun P., Florence X, et al.; Selective pancreatic ATP-sensitive-potassium channel openers for the treatment of glucose homeostasis disorder. Drugs Fut. 2006;31:991-1001.
[9] Bienengraeber M., Olson TM., Selivanov VA, et al.; ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet.
2004; 36(4):382-387.
[10] Gok S., Vural K., Sekuri C., Onur R., et al.; Effects of the blockade of cardiac sarcolemmal ATP-sensitive potassium channels on arrhythmias and coronary flow in ischemia-reperfusion model in isolated rat hearts. Vascul. Pharmacol. 2006;44(4):197-205.
[11] Yokoshiki H., Sunagawa M., Seki T., Sperelakis N.; ATP- sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am. J. Physiol., 1998, 274, C25. [12] Von Cuong D., Kim N., Joo H., Joum J.B., Choung J.Y., Lee Y., Park W.S., Kim E., Park J.S., Han S. Mitochondrion, 2005, 5, 121.
[13] Cole W., McPherson C., Sontag D; ATP-regulated K+ channels protect the myocardium against ischaemia/ reperfusion damage. Circ. Res. 1991;69:571-81.
45
[14] Murry CE., Jennings RB., Reimer KA; Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 1986;74:1124–36.
[15]Lochner A., Marais E., Genade S., Moolman J.A.. Am. J. Physiol. Heart Circ.
Cardiol., 2000, 279, H2752.
[16] Garlid KD, Paucek P., Yarov-Yarovoy V., Murray HN M., Darbenzio RB., D’Alonzo AJ., Lodge NJ., Smith MA., Grover GJ.; Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP sensitive K+ channels. Possible mechanism of cardioprotection. Circ. Res., 1997, 81, 1072-1082.
[17] Kumar V., MBBS, MD, FRCPath, Abul K. Abbas, MBBS, Nelson N., MD. “Robbins e Cotran- Le basi patologiche delle malattie- Patologia generale” 7a
Ed. Eusebi, MD, FRCPath. Elsevier, 17- 23.
[18] Mannhold R.. Med. Res. Rev., 2004, 24, 213.
[19] Bergmann R., Gericke R.; The influence of substituents in 3-position on the activity of chroman-type potassium channel activators. J. Med. Chem., 327:169-173. [20] Buckle D.R., Eggleston D.S., Houge-Frydrych C.S.V., Pinto I.L., Readshaw S.A.; Smith D.G., Webster R.A.B. J. Chem. Soc. Perkin Trans I, 1991, 1: 2763-2771.
[21] Petersen H.J., Nielsen C.K., Arrigoni-Martelli E.; synthesis and hypotensive activity of N-alkyl-N’’-cyano-N’-pyridylguanidines. J. Med. Chem., 1978, 21, 773. [22] Paucek P., Bajgar R., Seetharaman S., Grover G., Smith M.A., Steph P.G, Garlid K.D. J. Mol. Cell. Cardiol., 2001, 33, A91.
[23] Oldenburg O., Yang XM, Krieg T, Garlid KD., Cohen MV., Grover GJ, Downey J.M.; p1075 opens mitochondrial K(ATP)channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts. J. Mol. Cell. Cardiol., 2003, 35, 1035.
[24] Khan S.A., Higdon N.R., Hester J.B., Meisheri K.D. J. Pharmacol. Exp. Ther.,
1997, 283, 1207.
[25] Mannhold R. Med. Res. Rev., 2004, 24, 213.
[26]Miura K., Koyama H., Sugai T., Yamada H., Sakurai E., Horigome M., 1990,
European Patent 385350.
[27] Ito Y., Kato H., Etsuchu E., Ogawa N., Mitani K., Iwasaki N., Seiyaku H., 1991,
Japanese Patent. 89056667-A.
[28] Satake N., Kiyoto S., Zhou Q., Matsuo M., Shibata S. FASEB J. 1992,6,360
46
[29] Yao Z., Gross G.J. Circulation, 1994, 89, 1769.
[30] Garlid K.D., Paucek P., Yarov-Yarovoy V., Sun X., Schindler P.A. J. Biol. Chem.,
1996, 271, 8796.
[31] D’Hahan N., Moreau C., Prost A.L., Jacquet H., Alekseev A.E., Terzic A., Vivaudou M. Proc. Natl. Acad. Sci., 1999, 96, 12162.
[32] Aloup J.C., Farge D., James C., Mondot S., Cavero I. Drugs Fut.1990, 15,1097-1108.
[33] Atwal K.S., Grover G.J., Ahmed S.Z., Ferrara F.N., Harper T.W., Kim K.S., Sleph P.G., Dzwonczyk S., Russell A.D., Moreland S., McCullough J.R., Normandin D.E. J.
Med. Chem., 1993, 36, 3971.
[34] Grover G.J., D’Alonzo A.J., Garlid K.D., Bajgar R., Lodge N.J., Sleph P.G., Darbenzio R.B., Hess T.A., Smith M.A., Paucek P., Atwal K.S. J. Parmacol. Exp.
Ther., 2001, 297, 1184.
[35] Sato T., Costa A.D.T., Saito T., Ogura T., Ispida H., Garlid K.D., Nakaya H. J.
Pharmacol. Exp. Ther., 2006, 316, 182.
[36] Jauburek M., Yarov-Yarovoy V., Paucek P., Garlid K.D. J.Biol. Chem., 1998, 273, 13578.
[37] Gogelein H., Ruetten H., Albus U., Englert H.C., Busch A.E. Naunyn Schiedebergs
Arch. Pharmacol., 2001, 364, 33.
[38] Breschi M.C., Calderone V., Martelli A., Minutolo F., Rapposelli S., Testai L., Tonelli F., Balsamo A.. J. Med. Chem., 2006, 49,7600-7602.
[39] Calderone V.,Testai L., Martelli A., Rapposelli S., Digiacomo M., Balsamo A., Breschi M.C. J. Bioch. Pharmacol., 2010, 39-47.
[40] Magda A.-A. Sayed, Naglaa I. Abdel-Aziz, Alaa A.-M. Abdel-Aziz, Adel S. El-Azab, Yousif A. Asiri, Kamal E.H. ElTahir. Biorganic Med., Chem, 2011,19, 3416-3424.
[41] Syed Shafi, Mohammad Mahboob Alam, Naveen Mulakayala, Chaitanya Mulakayala, G. Vanaja, Arunasree M. Kalle, Reddanna Pallu, M.S. Alam. Eur. J Med.
Chem., 2012, 49, 324-333.
[42] Adriane R Todeschini, Ana Luisa P de Miranda, Kelly Christine M da Silva, Sergio C Parrini, Eliezer J Barreiro. Eur. J.Med.Chem, 1998,33,189-199.
47
[43] Ammazzalorso A., Amoroso R., Baraldi M., Bettoni G., Braghiroli D., De Filippis B., Giampietro L., Tricca M.L. and Vezzalini F.; Synthesis and antiplatelet activity of thioaryloxyacids analogues of clofibric acid. Eur. J Med. Chem., 2005, 40, 918-921. [44](Patent) Medicinal uses of Hydrazones, US,6,660,737,2003.
